Drugs / Leukovorin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00689624 | Jul 2007 → Dec 2010 | colorectal cancer | University Hospital of Crete | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01481272 Background | Nov 2011 → Jul 2017 | diffuse large B-cell lymphoma | Polish Lymphoma Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00388700 Background | Oct 2006 → Jun 2009 | colorectal cancer | Galectin Therapeutics Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00689624 ↗ |
| Route | Intravenous | “2-hour IV infusion” NCT00689624 ↗ |